Skip to Content

Avelumab Pregnancy and Breastfeeding Warnings

Avelumab is also known as: Bavencio

Avelumab Pregnancy Warnings

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug should be used during pregnancy only if the benefit outweighs the risk. US FDA pregnancy category: Not assigned. Risk Summary: Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Human IgG1 immunoglobulins (IgG1) are known to cross the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus. Comments: -Females of reproductive potential should use effective contraception during therapy with this drug and for at least one month after the last dose. -If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.

See references

Avelumab Breastfeeding Warnings

Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown Comments: -The effects in the nursing infant are unknown. -There is no information regarding the presence of this drug in human milk or the effects on milk production. -Advise a woman not to breastfeed during treatment and for at least one month after the last dose due to the potential for serious adverse reactions in breastfed infants.

See references

References for pregnancy information

  1. "Product Information. Bavencio (avelumab)." EMD Serono Inc, Rockland, MA.

References for breastfeeding information

  1. "Product Information. Bavencio (avelumab)." EMD Serono Inc, Rockland, MA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.